Benitec May Change HCV Paradigm Again With Single-Dose, DNA-Directed RNAi
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Australian biotech recently got FDA authorization to move its first (dd)RNA candidate, TT-034, into clinical development for hepatitis C. Dosing in a 14-patient, five-cohort, Phase I/IIa study will begin in mid-March and produce final data in about 18 months.